Fact CheckerSign in

NCT06536595Completed

Validity and Reliability of the Turkish Version of HAnDE

Validity and Reliability of the Turkish Version of the Hand Scleroderma Lived Experience Scale

Source: ClinicalTrials.gov · Last updated 9 Aug 2024

Brief summary (registry, in English)

The aim of the present study was to translate and cross-culturally adapt The Hand Scleroderma Experienced Experience (HAnDE) Scale into the Turkish language and investigate its reliability and validity in Turkish-speaking patients with systemic sclerosis.

Status (registry)
Completed
Study type
Observational
Enrollment
77 (actual)
First submitted
29 Jul 2024
Start date
1 Feb 2022
Primary completion date
1 Jun 2022
Lead sponsor
Gazi University
NCT number
NCT06536595

What you commit to

  • Study type: Observational
  • Participants enrolled: 77
  • From 1 Feb 2022 to the primary completion date, 1 Jun 2022
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • 1\) being in a psychological or cognitive disorders that would prevent to answer questions.

Who the study is looking for

  • 1\) being 18-65 years of age,
  • 2\) being diagnosed of SSc according to do 2013 American College of Rheumatology (ACR) criteria and/or European League Against Rheumatism (EULAR) criteria,
  • 3\) being literate in Turkish,
  • 4\) being agreed to participate in the research.

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Amasya University
Coordinator of this site? Confirm its status
AmasyaTurkey (Türkiye)Unknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.